Suppr超能文献

治疗慢性完全性冠状动脉闭塞的新方法。

Novel approaches for the treatment of chronic total coronary occlusions.

作者信息

Segev Amit, Strauss Bradley H

机构信息

Heart Institute, Chaim Sheba Medical Centre, Tel-Hashomer, Sackler School of Medicine, Tel-Aviv University, Israel.

出版信息

J Interv Cardiol. 2004 Dec;17(6):411-6. doi: 10.1111/j.1540-8183.2004.04084.x.

Abstract

Despite major advancements in the technology used for the percutaneous treatment of coronary artery disease, chronic total occlusions (CTOs) persist as a major challenge to the interventional cardiologist with relatively low success rates. CTOs are evident in 20% of patients undergoing cardiac catheterization and are responsible for the majority of cases that are referred to bypass surgery. There is growing evidence that patients may benefit from recanalization of a CTO by alleviation of angina, improving left ventricular function, and potentially long-term survival. The major obstacle to percutaneous recanalization of CTOs is the inability to cross the occlusion with coronary guidewires. Even when crossed, the operator has to deal with the exact location of the distal wire (e.g., dissection or true lumen) and the existence of relatively long lesion requiring multiple stents with high restenosis rates. New technologies for CTO revascularization have been focused mainly on a mechanical approach including specialized guidewires and more recently, specific devices using highly sophisticated technology such as laser guidewire, optical coherence reflectometry, and a blunt microdissection catheter. An alternate biological approach involves the local administration of enzymes such as plasminogen activators (urokinase) or collagenase, which can act locally to specifically degrade the collagen content of the CTO, thereby "softening" the occlusion and allowing easier guidewire crossing. In conclusion, CTOs emerge as a great technical challenge and are the focus of novel series of mechanical and biological approaches.

摘要

尽管用于经皮冠状动脉疾病治疗的技术取得了重大进展,但慢性完全闭塞(CTO)仍然是介入心脏病专家面临的重大挑战,成功率相对较低。在接受心脏导管插入术的患者中,20%存在CTO,并且大多数转介至搭桥手术的病例都与之有关。越来越多的证据表明,患者可能会从CTO再通中受益,包括缓解心绞痛、改善左心室功能以及潜在的长期生存。CTO经皮再通的主要障碍是无法用冠状动脉导丝穿过闭塞病变。即使穿过了闭塞病变,术者仍需处理导丝远端的确切位置(如夹层或真腔),以及存在需要多个支架且再狭窄率高的相对较长病变。CTO血管重建的新技术主要集中在机械方法上,包括专门的导丝,以及最近使用高度复杂技术的特定设备,如激光导丝、光学相干反射仪和钝头微解剖导管。另一种生物学方法是局部应用酶,如纤溶酶原激活剂(尿激酶)或胶原酶,它们可以在局部起作用,特异性降解CTO的胶原蛋白含量,从而“软化”闭塞病变,使导丝更容易穿过。总之,CTO是一个巨大的技术挑战,也是一系列新型机械和生物学方法的焦点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验